Objective:　Although　there　are　certain　drug　categories　associated　with　heart　failure　(HF),　most　of　the　associated　risks　are　unclear.　We　investigated　the　top　drugs　associated　with　HF　and　acute　HF　(AHF)　reported　in　the　FDA　Adverse　Event　Reporting　System　(FAERS).　Methods:　We　reviewed　publicly　available　FAERS　databases　from　2004　to　2023.　Using　the　search　terms　＂cardiac　failure＂　or　＂cardiac　failure　acute＂　and　classifying　cases　by　drug　name,　we　processed　and　analyzed　drug　reports　related　to　HF　or　AHF.　Results:　From　2004　to　2023,　17,379,609　adverse　drug　events　were　reported　by　FAERS,　of　which　240,050　(1.38%)　were　reported　as　HF.　Among　those　with　HF,　the　male-to-female　ratio　was　0.94%　and　52.37%　were　＞65　years　old;　46.2%　were　from　the　United　States.　There　were　5,971　patients　with　AHF.　We　identified　38　drugs　and　13　drug　classes　with　a　potential　high　risk　of　causing　HF,　and　41　drugs　and　19　drug　classes　were　associated　with　AHF.　The　median　onset　times　of　HF　and　AHF　were　83　days　(IQR:　11-416)　and　49　days　(IQR:　8-259),　respectively.　The　Weibull　shape　parameter　(WSP)　test　showed　early　failure-type　profile　characteristics.　Conclusion:　This　study　highlights　key　drugs　associated　with　drug-induced　HF　and　AHF,　emphasizing　the　importance　of　early　risk　assessment　and　close　monitoring,　particularly　during　the　initial　stages　of　treatment.　These　findings　contribute　to　a　better　understanding　of　drug-induced　HF　and　provide　a　basis　for　future　research　on　its　underlying　mechanisms.